From AlphaFold to site-selective inhibition of DNA methylation in glioblastoma multiforme

Jean-Maxime Besson; Alain Chavanieu; Arulraj Nadaradjane; Pierre‐François Cartron; Marie Lopez

doi:10.1039/d5md00988j

January 1, 2026RSC Medicinal Chemistry

From AlphaFold to site-selective inhibition of DNA methylation in glioblastoma multiforme

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore targeted inhibition of DNA methyltransferases to enhance glioblastoma multiforme cell sensitivity to temozolomide.
Targeted protein-protein interactions were examined using advanced computational tools such as AlphaFold.
Specific inhibitors were developed to selectively inhibit DNA methyltransferases in vitro.
The study involved testing these inhibitors on glioblastoma multiforme cell lines.
The use of site-selective inhibitors led to a significant resensitization of glioblastoma multiforme cells to temozolomide treatment.
Inhibited cells showed reduced DNA methylation levels, correlating with improved drug efficacy.

Implication

Study targets DNA methyltransferases to improve response to temozolomide in glioblastoma multiforme, indicating potential for enhanced treatment outcomes.

Abstract

Targeting specific protein–protein interactions, particularly those involving DNA methyltransferases (DNMTs), offers a promising strategy to resensitise glioblastoma multiforme cells to temozolomide.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Besson et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf4aefaef96ed7f056d96 https://doi.org/10.1039/d5md00988j

View Full Paper

Ask AI

Bookmark

Share

From AlphaFold to site-selective inhibition of DNA methylation in glioblastoma multiforme

Key Points

Implication

Abstract

Discussion

Cite This Study

From AlphaFold to site-selective inhibition of DNA methylation in glioblastoma multiforme

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading